Macrogenics (MGNX) Profit After Tax (2012 - 2026)
Macrogenics (MGNX) reported Profit After Tax of -$36.8 million for Q1 2026, up 10.39% year-over-year from -$33.3 million in Q1 2025, and down 159.8% quarter-over-quarter from -$14.2 million in Q4 2025.
Macrogenics (MGNX) Profit After Tax (2012 - 2026) Analysis & Trends
Macrogenics (MGNX) has 15 years of Profit After Tax data on file, last reported at -$36.8 million in Q1 2026.
- Profit After Tax for Q1 2026 came in at -$36.8 million, up 10.39% year-over-year; the trailing twelve-month figure through Mar 2026 was -$70.4 million (down 26.06% YoY), and the FY2025 annual result was -$74.6 million, down 11.43% from the prior year.
- Profit After Tax retreated to -$36.8 million in Q1 2026 per MGNX's latest filing, from -$14.2 million in the prior quarter.
- Over five years, Profit After Tax peaked at $57.5 million in Q2 2023 and troughed at -$66.4 million in Q1 2022.
- A 5-year average of -$18.1 million and a median of -$36.3 million in 2025 frame the typical range for Profit After Tax.
- On a YoY basis, Profit After Tax climbed as much as 239.14% in 2023 and fell as far as 459.88% in 2023.
- A 5-year view of Profit After Tax shows it stood at $12.8 million in 2022, then sank by 459.88% to -$46.1 million in 2023, then soared by 66.53% to -$15.4 million in 2024, then increased by 8.21% to -$14.2 million in 2025, then slumped by 159.8% to -$36.8 million in 2026.
- Business Quant data shows MGNX's Profit After Tax at -$36.8 million in Q1 2026, -$14.2 million in Q4 2025, and $16.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.90 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.63 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -753,254.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.74 Mn |
| 10 | Macrogenics | 260.14 Mn | 193.63 Mn | - | -36.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -36.77 Mn |
| Dec 31, 2025 | -14.16 Mn |
| Sep 30, 2025 | 16.82 Mn |
| Jun 30, 2025 | -36.25 Mn |
| Mar 31, 2025 | -41.04 Mn |
| Dec 31, 2024 | -15.42 Mn |
| Sep 30, 2024 | 56.31 Mn |
| Jun 30, 2024 | -55.66 Mn |
| Mar 31, 2024 | -52.19 Mn |
| Dec 31, 2023 | -46.07 Mn |
| Sep 30, 2023 | 17.55 Mn |
| Jun 30, 2023 | 57.47 Mn |
| Mar 31, 2023 | -38.01 Mn |
| Dec 31, 2022 | 12.80 Mn |
| Sep 30, 2022 | -24.81 Mn |
| Jun 30, 2022 | -41.30 Mn |
| Mar 31, 2022 | -66.44 Mn |
| Dec 31, 2021 | -58.02 Mn |
| Sep 30, 2021 | -52.89 Mn |
| Jun 30, 2021 | -39.94 Mn |